Abstract
We address the issue of the potential for malignant transformation of cultured mesenchymal stromal cells (MSC) commonly used in clinical cell-therapy protocols and describe the culture conditions under which tumorigenesis is likely to be an extremely uncommon event. © 2010 Informa Healthcare.
Author supplied keywords
Cite
CITATION STYLE
APA
Prockop, D. J., Brenner, M., Fibbe, W. E., Horwitz, E., Le Blanc, K., Phinney, D. G., … Keating, A. (2010). Defining the risks of mesenchymal stromal cell therapy. Cytotherapy, 12(5), 576–578. https://doi.org/10.3109/14653249.2010.507330
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free